Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.
Employees - 41,
CEO - Mr. Carmine N. Stengone MBA, MS,
Sector - Healthcare,
Country - US,
Market Cap - 99.09M
Altman ZScore(max is 10): 3.83, Piotroski Score(max is 10): 4, Working Capital: $183185000, Total Assets: $198264000, Retained Earnings: $-133392000, EBIT: -51951000, Total Liabilities: $13496000, Revenue: $242000
AryaFin Target Price - $0.81 - Current Price $3.83 - Analyst Target Price $23.80
| Ticker | CTNM |
| Index | RUT |
| Curent Price | 3.83 |
| Change | -12.36% |
| Market Cap | 99.09M |
| Average Volume | 73.48K |
| Income | -49.83M |
| Sales | 0.00M |
| Book Value/Share | 7.14 |
| Cash/Share | 7.37 |
| Dividend Est | - |
| Dividend TTM | - |
| Dividend Ex-Date | - |
| Employees | 41 |
| Moving Avg 20days | -6.00% |
| Moving Avg 50days | -28.08% |
| Moving Avg 200days | -68.91% |
| Shares Outstanding | 19.14M |
| Earnings Date | May 14 AMC |
| Inst. Ownership | 43.20% |
| Price/Earnings | - |
| Forwad P/E | - |
| PE Growth | - |
| Price/Sales | - |
| Price/Book | 0.54 |
| Price/Cash | 0.52 |
| Price/FCF | - |
| Quick Ratio | 21.47 |
| Current Ratio | 21.47 |
| Debt/Equity | 0.03 |
| Return on Assets | -30.97% |
| Return on Equity | -91.32% |
| Return on Investment | -26.32% |
| Gross Margin | - |
| Ops Margin | - |
| Profit Margin | - |
| RSI | 41.22 |
| BETA(β) | 1.10 |
| From 52week Low | 11.82% |
| From 52week High | -82.59% |
| EPS | -1.93 |
| EPS next Year | -3.01 |
| EPS next Qtr | -0.45 |
| EPS this Year | -11.62% |
| EPS next 5 Year | -8.65% |
| EPS past 5 Year | - |
| Sales past 5 Year | -50.00% |
| EPS Y/Y | -294.54% |
| Sales Y/Y | -100.00% |
| EPS Q/Q | -88.91% |
| Sales Q/Q | - |
| Sales Surprise | - |
| EPS Surprise | -9.73% |
| ATR(14) | 0.49 |
| Perf Week | 0.52% |
| Perf Month | -22.63% |
| Perf Quarter | -48.31% |
| Perf Year | -74.40% |
| Perf YTD | -73.86% |
| Target Price | 23.80 |
AryaFin Engine© - An AI FinTech Venture - 2024-25 Disclaimer